Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.

Akifumi NakamuraMasaki HashimotoNobuyuki KondoSeiji MatsumotoAyumi KurodaToshiyuki MinamiKazuhiro KitajimaKozo KuribayashiTakashi KijimaSeiki Hasegawa

Published in: International journal of clinical oncology (2023)

Nivolumab with ipilimumab treatment in patients with recurrent MPM after primary surgical treatment may be clinically efficacious, although serious AEs may be frequently observed.

Keyphrases

randomized controlled trial
combination therapy
replacement therapy